RESEARCH OF THE LONG-TERM OUTCOMES OF PORTOSYSTEMIC SHUNTING DEPENDING ON THE ETIOLOGY OF LIVER CIRRHOSIS
Keywords:
liver cirrhosis, portal hypertension, portosystemic shuntingAbstract
Purpose. Conduct a summary analysis of the results after the portosystemic shunting depending on the etiology of liver cirrhosis. Material and methods. The study selected 109 patients with cirrhosis of the liver, operated operated by the RSSPMCS named after acad. V.Vakhidov in 2014-2017. With hepatitis B, B + D and C - 72 patients. To compare the features of the course of the late postoperative period, the study included patients with alcoholic cirrhosis of the liver (n = 21) and idiopathic form (n = 16). Results. In hepatitis B liver cirrhosis within 5 years after portosystemic shunting, 10 out of 32 (31.3%) patients died, in HBV and HDV cirrhosis - 18 out of 26 (69.2%), HCV - 4 out of 14 (28, 6%), alcoholic– 7 out of 21 (33.3%) and idiopathic - 4 out of 16 (25%) patients. In the structure of mortality in HBV, hepatic failure accounted for 21.9% (7 of 32) cases, hemorrhagic syndrome - 9.4% (3), with HBV and HDV cirrhosis, these figures were 53.8% (14 of 26) and 15.4% (4) respectively, with HCV - 21.4% (3 out of 14) and 7.1% (1), with alcoholic - 23.8% (5 out of 21) and 9.5% (2) and for idiopathic, 12.5% (2 of 16) and 12.5% (2). A total of 66 (60.6%) patients were alive in all species in terms of 5 years of follow-up after surgery, the mortality rate was 39.4% (43 of 109 patients).
References
Гусев 2001; Гусев Д.А. Клинико-лабораторная и морфологическая характеристика манифестных форм микст-гепатита В+С у лиц молодого возраста.: Автореф. дис. ... канд. мед. наук. - Санкт-Петербург. 2001. 20 с.
Сернов С.П., Лифшиц В.Б., Скворцов Ю.И. с соавт. Актуальные проблемы прогнозирования алкогольной болезни печени. Саратовский научно-медицинский журнал. 2010;1(6):94-100.
Ferenci P. Hepatic encephalopathy. Gastroenterology Report. 2017; 5(2): 138–147.
Garcia-Tsao G., Lim J. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the department of veterans affairs hepatitis C resource center program and the national hepatitis C program. American Journal of Gastroenterology, 2009; 104(7):1802–1829.
Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatol., 2009; 49:1335-1374.
Liaw YF, Chang TT, Wu SS et al. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg(+) and (–) chronic hepatitis B: results from studies ETV-022, – 027 and – 901. Hepatol. 2008; 48(1): 706A.
Merchante N, Rivero-Juárez A, Téllez F et al. Liver stiffness predicts clinical outcome in human immunodeficiency virus hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatol. 2012; 56(1):228-238.
Mochida S, Takaguchi K, Yokosuka O et al. Long term efficacy, safety and resistance analyses of entecavir treatment in Japanese nucleoside-naive patients with chronic hepatitis B. Hepatol. 2008;48(2):262.
O'Leary JG, Davis GL. Hepatitis C. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease . 9th ed. Philadelphia, Pa: Saunders Elsevier, 2010. - chap 79.
Rosen HR. Clinical practice. Chronic hepatitis C infection. N. Engl. J. Med. 2011; 364(25): 2429-38.
Schiff ER, Lee SS, Chao YC, et al.: Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin. Gastroenterol. Hepatol.2011;9: 274-6.
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008; 371(9615):838–851.
Sohrabpour AA, Mohamadnejad M, Malekzadeh R. Review article: the reversibility of cirrhosis. Aliment. Pharmacol. Ther. 2012; 36: 824-32.
